Summary of Study ST000282
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000224. The data can be accessed directly via it's Project DOI: 10.21228/M8K599 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
Study ID | ST000282 |
Study Title | Pilot Study 13C flux effects when RhoC or RhoA perturbed (13C BCs) |
Study Type | 13C mass isotopomer analysis (flux studies) |
Study Summary | Rho-GTPases are small GTP-binding proteins that contribute to the epithelial-to-mesenchymal transition by regulating several cellular processes including organization of the actin cytoskeleton, cell motility, transcription, and cell proliferation. Overexpression of RhoC-GTPases (RhoC) in breast cancer has been implicated in poor disease prognosis due to increased cancer cells invasion, migration, and motility, which warranted its consideration as a therapeutic target for inhibiting breast cancer metastasis. Using silencing RNA (siRNA) molecules to knockdown RhoC expression is a promising approach to inhibit breast cancer metastases. |
Institute | University of Michigan |
Department | Internal Medicine |
Laboratory | Merajver Lab |
Last Name | Wynn |
First Name | Michelle |
Address | University Michigan, 2900 Huron Parkway, Ann Arbor, MI 48105 |
mlwynn@umich.edu | |
Phone | 734-647-3408 |
Submit Date | 2015-02-11 |
Num Groups | 5 |
Total Subjects | 16 |
Raw Data File Type(s) | d |
Analysis Type Detail | GC-MS/LC-MS |
Release Date | 2016-01-13 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Treatment:
Treatment ID: | TR000316 |